about
Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients.Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma.Optimizing immunotherapy in multiple myeloma: Restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cellsAdvances in immunotherapy of multiple myeloma: from the discovery of tumor-associated antigens to clinical trials.Roles of idiotype-specific t cells in myeloma cell growth and survival: Th1 and CTL cells are tumoricidal while Th2 cells promote tumor growth.DKK1 as a novel target for myeloma immunotherapy.Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma.
P2860
Q34075717-58CEDC86-DBDF-4B99-BC10-C2E203502A46Q35651705-7F177C8A-3461-4EEE-B453-529F39FC6B74Q35848756-C54A541A-9692-4B59-AC4F-5B97C8A5B479Q36844954-E737B646-EC7A-474D-83AF-FA071303F69DQ36955402-9864410C-2765-4101-AF61-754830C421A5Q42156831-220197D6-59AD-4F81-9065-151155E669B4Q42741820-9B6EFFD2-E51D-4F38-8D78-6BB596F1C18F
P2860
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Dendritic cell-based immunotherapy in multiple myeloma.
@ast
Dendritic cell-based immunotherapy in multiple myeloma.
@en
type
label
Dendritic cell-based immunotherapy in multiple myeloma.
@ast
Dendritic cell-based immunotherapy in multiple myeloma.
@en
prefLabel
Dendritic cell-based immunotherapy in multiple myeloma.
@ast
Dendritic cell-based immunotherapy in multiple myeloma.
@en
P2860
P1433
P1476
Dendritic cell-based immunotherapy in multiple myeloma.
@en
P2093
P2860
P304
P356
10.1080/1042819031000116599
P577
2003-12-01T00:00:00Z